Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors (Q27676858)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors	scientific article

Statements

instance of

scholarly article

0 references

title

Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors (English)

0 references

main subject

drug discovery

0 references

author name string

Rongshi Li

series ordinal

1

0 references

Mathew P Martin

series ordinal

2

0 references

Yan Liu

series ordinal

3

0 references

Binglin Wang

series ordinal

4

0 references

Ronil A Patel

series ordinal

5

0 references

Jin-Yi Zhu

series ordinal

6

0 references

Nan Sun

series ordinal

7

0 references

Roberta Pireddu

series ordinal

8

0 references

Nicholas J Lawrence

series ordinal

9

0 references

Jiannong Li

series ordinal

10

0 references

Eric B Haura

series ordinal

11

0 references

Shen-Shu Sung

series ordinal

12

0 references

Wayne C Guida

series ordinal

13

0 references

Ernst Schonbrunn

series ordinal

14

0 references

Said M Sebti

series ordinal

15

0 references

language of work or name

English

0 references

publication date

8 March 2012

0 references

published in

Journal of Medicinal Chemistry

0 references

volume

55

0 references

issue

5

0 references

page(s)

2474-8

0 references

cites work

Fragment-based discovery of BACE1 inhibitors using functional assays

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

20 March 2017

Identification of inhibitors of checkpoint kinase 1 through template screening

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

20 March 2017

Fragment-based identification of Hsp90 inhibitors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

20 March 2017

The structure of dimeric ROCK I reveals the mechanism for ligand selectivity

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

20 March 2017

Q28649301

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

20 March 2017

Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Fragment screening by surface plasmon resonance

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Native Ms: An ‘Esi’ Way to Support Structure- and Fragment-Based Drug Discovery

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Weak affinity chromatography as a new approach for fragment screening in drug discovery

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

ROCK inhibitors as emerging therapeutic candidates for sarcomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Target immobilization and NMR screening of fragments in early drug discovery

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Rho kinase (ROCK) inhibitors and their application to inflammatory disorders

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Fragment-based screening using X-ray crystallography and NMR spectroscopy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

A decade of fragment-based drug design: strategic advances and lessons learned

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Design and synthesis of Rho kinase inhibitors (II).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

The art and practice of structure-based drug design: A molecular modeling perspective

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

29 September 2017

Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

27 November 2018

Adding calorimetric data to decision making in lead discovery: a hot tip

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

27 November 2018

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

27 November 2018

Fragment-based drug design: how big is too big?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

27 November 2018

Design and synthesis of Rho kinase inhibitors (I).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516226

retrieved

27 November 2018

Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/22272748

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1021/JM201289R

0 references

PMC publication ID

4516226

0 references

PubMed publication ID

22272748

0 references

ResearchGate publication ID

221773162

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27676858&oldid=1412099592"